A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

Author： Tilden Dominic P.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.1, 2007-01, pp. : 39-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

By Home Philip  

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 801-802

Adis International

Access to resources Recommend Favorite

Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

By Derosa G   D'Angelo A   Ragonesi PD   Ciccarelli L   Piccinni MN   Pricolo F   Salvadeo S   Montagna L   Gravina A   Ferrari I   Galli S   Paniga S   Cicero AFG  

The Journal of International Medical Research, Vol. 34, Iss. 5, 2006-09 ,pp. : 545-555

Field House Publishing

Access to resources Recommend Favorite

Pioglitazone pays dividends in type 2 diabetes mellitus

By  

Inpharma, Vol. 1, Iss. 1612, 2007-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Pioglitazone pays dividends in type 2 diabetes mellitus

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 540, 2007-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Pioglitazone wins out over rosiglitazone in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite